<DOC>
	<DOCNO>NCT00774462</DOCNO>
	<brief_summary>The traditional treatment inflammatory myopathy ( IM ) generalize myasthenia gravis ( MG ) immunosuppressive therapy , usually begin corticosteroid . However , 70 % treat patient show incomplete response , include 10 - 30 % unresponsive . Corticosteroids immunosuppressive therapy present also many side effect . We propose evaluate pilot , open , prospective , multicentric , phase II study , interest rituximab treatment patient primary IM associate specific AAb ( anti-synthetase anti-SRP AAbs ) , MG ( anti-AchR AAbs ) , refractory conventional therapy . Twenty fourth patient primary IM ( 12 anti-synthetase , 12 anti-SRP AAbs ) , 12 MG include study .</brief_summary>
	<brief_title>Rituximab Treatment Refractory Inflammatory Myopathies Refractory Myasthenia Gravis</brief_title>
	<detailed_description>Rituximab , chimeric monoclonal antibody specific human CD20 , target B lymphocyte , first developed biotherapy treatment B lymphoma . In context , hundred thousand patient receive drug , good tolerance . Recently , interest grow pivotal role B cell auto-immune humorally mediate disease . Rituximab could potential new biological treatment disease , especially patient refractory conventional therapy . As Muscular Diseases Centre , large recruitment patient inflammatory myopathy ( IM ) myasthenia gravis ( MG ) . Although physiopathogenesis two condition differ , associate specific auto-antibodies ( AAbs ) therapeutic management almost similar . The traditional treatment approach IM generalize MG immunosuppressive therapy , usually begin corticosteroid . However , 70 % treat patient show incomplete response , include 10 - 30 % unresponsive . We propose evaluate pilot , open , prospective , multicentric , phase II study , interest rituximab treatment patient primary IM associate specific AAb ( anti-synthetase anti-SRP AAbs ) , MG ( anti-AchR AAbs ) , refractory conventional therapy . Inclusions criterion IM ( define 119th European Neuromuscular Centre workshop ) generalise MG ( define Texas Clinical Classification System ) associate specific AAbs ( anti-synthetases ( JO1 , PL7 PL12 ) , anti-SRP primary IM , anti-AchR MG ) refractory conventional treatment define inadequate response , intolerable side effect conventional treatment , corticosteroid , azathioprine , methotrexate , cyclophosphamide , cyclosporine , IgIV and/or plasma exchange . The therapeutical schema rituximab 1000 mg , 2 time ( day 0 15 ) , follow one single injection ( 1000 mg ) 6 month latter end follow 1 year . The efficacy evaluate improvement Kendall 's muscular test MG muscular score month 12 . Secondary criterion include Kendall 's muscular test MG muscular score day 21 month 7 , quality life auto-questionnaire ( SF 36 ) , evolution CK level AAb titer . Twenty fourth patient primary IM ( 12 anti-synthetase , 12 anti-SRP AAbs ) , 12 MG include study . If success observe least 6 patient , possible conclude response rate 25 % ( low 90 % confidence interval observe response rate 50 % ) .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>For myositis III . Idiopathic myositis 1 . Myositis define 119th ENMC : 1 . Proximal myopathy weakness 2 . Subacute insidious onset 18 year 3 . Myogenic syndrome EMG ( optional ) 4 . Muscle fibre necrosis regeneration and/or inflammatory cell infiltrate muscular biopsy 2 . Specific AAbs : antisynthetases ( antiJO1 , antiPL7 , antiPL12 ) , antiSRP . IV . Refractory conventional treatment Resistance conventional treatment define inadequate response , intolerable side effect conventional treatment , corticosteroid , azathioprine , methotrexate , cyclophosphamide , cyclosporine , IgIV and/or plasma exchange . At least one drug therapeutical approach ( use alone combination ) must unsuccessfully test inclusion . Inadequate response define lack improvement and/or degradation evaluation parameter ( define bellow ) despite conventional therapy , lead modification reintroduction treatment . For myasthenia III . Generalised MG Generalised seropositive MG define Texas Clinical Classification System : 1 . Extraocular muscle weakness quantify MG muscle score ( MMS ) , whose inter inter observer reproducibility demonstrate [ 44 ] . 2 . Specific AAbs : antiAchR IV . Refractory conventional treatment Resistance conventional treatment define inadequate response , intolerable side effect conventional treatment , corticosteroid , azathioprine , methotrexate , cyclophosphamide , cyclosporine , IgIV and/or plasma exchange . At least one drug therapeutical approach ( use alone combination ) must unsuccessfully test inclusion . Inadequate response define lack improvement and/or degradation evaluation parameter ( define bellow ) despite conventional therapy , lead modification reintroduction treatment Other muscular disease , : 1 . Inclusion body myositis 2 . Macrophagic myofasciitis 3 . Inherited myopathy Secondary IM one connective tissue disorder 1 . Systemic scleroderma ( ARA and/or `` LEROY AND MEDSGER '' criterion ) 2 . Sj√∂gren 's syndrome ( European criterion ) 3 . Systemic lupus erythematosus ( ACR criterion ) 4 . Rheumatoid arthritis ( ACR criterion ) 5 . Mixed connective tissue disease ( ACR criterion ) Other myasthenic syndrome , : 1 . Non generalise , ocular MG 2 . Lambert Eaton syndrome 3 . MG associate malignant thymoma 4 . Inherited myasthenic syndrome Cancer ( cancerassociated myositis ) Age &lt; 18 year Pregnancy HIV seropositivity Evolutive infection ( B , C hepatitis , tuberculosis ) Lack approve consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Myositis</keyword>
	<keyword>Anti-synthetase</keyword>
	<keyword>Anti-SRP</keyword>
	<keyword>Myasthenia gravis</keyword>
	<keyword>Rituximab</keyword>
</DOC>